Skip to main content
. 2022 Apr 7;14(1):2057269. doi: 10.1080/19420862.2022.2057269

Figure 4.

Figure 4.

VEGF-Trap/moAb4 bispecific antibody significantly enhanced the anti-angiogenic efficacy of VEGF-Trap. a. Illustration showing the design of bispecific antibodies used in this figure. b. Immunofluorescent staining showing the level of fluorescently labeled albumin in U-87 MG tumors, which serves as an indicator of BBB integrity. Scale bar = 20 μm. The immunofluorescence data was quantified and showed in a bar graph, n = 3 independent mice. c. Immunofluorescent staining showing the level of CD31 in U-87 MG tumors. Scale bar = 20 μm. The immunofluorescence data was quantified and showed in a bar graph, n = 3 independent mice. Bar graphs with error bars represent mean ± SD. For the statistical analysis, ns = not statistically different, *** P < .001, two-tailed Student t-test.